Stay updated with breaking news from Form Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The company’s raised more than $225 million to date, and its backers include USIT, Bold Capital Partners, Breyer Capital, Bob Nelsen, At One Ventures, and more.
We also have incredible teams working on the Tasmanian tiger—or the thylacine—and the dodo.
Colossal Biosciences is still on track to bring the extinct animal to life by 2028. But CEO Ben Lamm says its investor deck isn’t for everyone.
FluidForm Bio, a leader in developing life-like human tissue to treat disease, shares recent advancements in building human cardiac tissues using FRESH™ 3D bioprinting.
FluidForm Bio, a leader in developing life-like human tissue to treat disease, shares recent advancements in building human cardiac tissues using FRESH™ 3D bioprinting.